S&CO Inc. Buys 2,000 Shares of Neurocrine Biosciences, Inc. $NBIX

S&CO Inc. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 40.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 7,000 shares of the company’s stock after acquiring an additional 2,000 shares during the period. S&CO Inc.’s holdings in Neurocrine Biosciences were worth $879,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $1,460,000. Assetmark Inc. lifted its holdings in Neurocrine Biosciences by 10.8% during the 2nd quarter. Assetmark Inc. now owns 21,001 shares of the company’s stock valued at $2,640,000 after purchasing an additional 2,045 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. bought a new position in Neurocrine Biosciences during the second quarter worth $696,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Neurocrine Biosciences by 229.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 19,107 shares of the company’s stock valued at $2,467,000 after purchasing an additional 13,301 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Neurocrine Biosciences by 61.9% in the second quarter. Envestnet Asset Management Inc. now owns 198,039 shares of the company’s stock valued at $24,891,000 after purchasing an additional 75,733 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NBIX. Stifel Nicolaus raised their target price on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Needham & Company LLC increased their price target on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada boosted their price objective on Neurocrine Biosciences from $156.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Finally, Morgan Stanley increased their target price on Neurocrine Biosciences from $163.00 to $168.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.26.

Neurocrine Biosciences Stock Down 1.6%

Shares of NASDAQ:NBIX opened at $152.37 on Monday. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $157.67. The company’s 50 day moving average price is $142.02 and its two-hundred day moving average price is $131.63. The firm has a market cap of $15.19 billion, a PE ratio of 36.45, a PEG ratio of 0.94 and a beta of 0.22.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.46. The company had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 earnings per share. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 300 shares of Neurocrine Biosciences stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $19,933,581.79. The trade was a 0.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William H. Rastetter sold 18,000 shares of the stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the sale, the director directly owned 40,360 shares in the company, valued at approximately $6,127,455.20. This trade represents a 30.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.80% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.